EQUITY OESTRUS CONTROL VACCINE FOR HORSES

البلد: أستراليا

اللغة: الإنجليزية

المصدر: APVMA (Australian Pesticides and Veterinary Medicines Authority)

العنصر النشط:

GNRF - PROTEIN CONJUGATE; THIOMERSAL

متاح من:

ZOETIS AUSTRALIA PTY LTD

INN (الاسم الدولي):

GnRF-protein conjugate(200ug/mL)

الشكل الصيدلاني:

PARENTERAL LIQUID/SOLUTION/SUSPENSION

تركيب:

GNRF - PROTEIN CONJUGATE BIOLOGICAL-PROTEIN Active 200.0 ug/ml; THIOMERSAL MERCURY Other 0.1 mg/ml

الوحدات في الحزمة:

1 x 10mL; 1 x 1mL; 10 x 1mL; 20 x 1mL

الفئة:

VM - Veterinary Medicine

المصنعة من قبل:

ZOETIS AUSTRALIA

المجموعة العلاجية:

HORSE FILLY (YOUNG FEMALE) | HORSE MARE (FEMALE) | FEMALE HORSE | HORSE - YOUNG FEMALE

المجال العلاجي:

ENDOCRINE SYSTEM

الخصائص العلاجية:

EQUINE OESTRUS CYCLE | CTRL OF OESTRUS REL.BEHAVIOUR

ملخص المنتج:

Poison schedule: 4; Withholding period: WHP: Meat: Nil.; Host/pest details: HORSE FILLY (YOUNG FEMALE): [EQUINE OESTRUS CYCLE]; HORSE MARE (FEMALE): [EQUINE OESTRUS CYCLE]; Poison schedule: 4; Withholding period: ; Host/pest details: HORSE FILLY (YOUNG FEMALE): [EQUINE OESTRUS CYCLE]; HORSE MARE (FEMALE): [EQUINE OESTRUS CYCLE]; An aid in the control of oestrus and oestrus related behaviour in fillies and mares not intended for breeding.Do not use this product in horses intended for breeding, or in pregnant mares.

الوضع إذن:

Registered

تاريخ الترخيص:

2023-07-01

نشرة المعلومات

APPENDIX 2
AUSTRALIAN GOVERNMENT
AUSTRALIAN PESTICIDES AND
VETERINARY MEDICINES AUTHORITY
TEMPLATE FOR RELEVANT LABEL PARTICULARS (RLPS)
(VETERINARY PRODUCTS)
Select appropriate:
CL
New Product (include all applicable RLPs)
OR
0 Variation (highlight instructions that are being varied). Approval
no.
of
label being varied: 53542/0108.
Signal
heading:
Product
name:
Active
constituenUs:
Statement
of
claims:
Net
contents:
Directions
for
Use
Heading:
Restraints:
CONTRAINDICATIONS:
PRECAUTIONS:
Side
effects:
Dosage
&
ADMINISTRATION:
PRESCRIPTION ANIMAL REMEDY
+
KEEP OUT OF REACH OF CHILDREN
READ SAFETY DIRECTIONS
FOR ANIMAL TREATMENT ONLY
U.WL
EQUITY® OESTRUS CONTROL VACCINE FOR HORSES
Approved
Equity Oestrus Control Vaccine for Horses is prepared from
an
analogue of gonadotropin
releasing
factor
(GnRF)
linked
to
a
carrier
protein.
It
is
adjuvanted
with
immunostimulating complex
to
increase the level and duration
of
immunity. Each mL
of
vaccine provides 200
11g
GnRF-protein conjugate.
Thiomersal
0.1
mg/mL has been added as a preservative.
An
aid
in
the control of oestrus and oestrus-related behaviour
in
fillies and mares not
intended for breeding.
Product
is
in 1
mL dose syringe
in
packs of
1,
10 or 20.
Product
is
also
in
1
OmL
dose vial.
DIRECTIONS FOR USE
READ THE ENCLOSED LEAFLET BEFORE USING THIS PRODUCT
Contents must
be
left
in
outer package until immediately before
use.
N/A
Do
not use this product in horses intended for breeding, or
in
pregnant mares. The long
term effect
of
this product
on
fertility
in
breeding horses
is
poorly known and effect may
be
extended for multiple breeding seasons. The extent and duration
of
effect
of
booster
doses of vaccine have not been studied.
N/A
Some swelling may develop at the site of vaccination
in
a small number
of
horses but
resolves quickly, usually within a few days.
The dose
on
all occasions is 1 mL injected intramuscularly.
The most convenient site for
injection
is
the centre of the side of the neck. Before the vaccine
is
injected, the proposed
site of inoculation
on
the

خصائص المنتج

PRODUCT NAME: EQUITY
® OESTRUS CONTROL VACCINE FOR HORSES
PAGE: 1 OF 5
THIS REVISION ISSUED:
MATERIAL SAFETY DATA SHEET
Issued by: Pfizer Australia Pty Ltd
Phone: [phone]
SECTION 1 - IDENTIFICATION OF CHEMICAL PRODUCT AND COMPANY
Pfizer Australia Pty Ltd
38-42 Wharf Road
West Ryde NSW 2114
Tel: [phone]
Fax: [phone]
____________________________________
PFIZER AUSTRALIA PTY LTD
A.B.N. 50 008 422 348
SUBSTANCE:
Equine hormones in water solution.
TRADE NAME:
EQUITY
® OESTRUS CONTROL VACCINE FOR HORSES
PFIZER MSDS CODE:
0814
PRODUCT USE:
For use in the control of oestrus and oestrus-related behavior in
fillies and mares not
intended for breeding.
CREATION DATE:
JULY, 2004
THIS VERSION ISSUED
APRIL 2010
and is valid for 5 years from this date.
SECTION 2 - HAZARDS IDENTIFICATION
STATEMENT OF HAZARDOUS NATURE
This product is classified as:
Hazardous according to the criteria of SWA Australia.
Not a Dangerous Good according to the Australian Dangerous Goods (ADG)
Code.
RISK PHRASES:
R62, R63. Possible risk of impaired fertility. Possible risk of harm
to the unborn child.
SAFETY PHRASES:
S24/25. Avoid contact with skin and eyes.
SUSDP CLASSIFICATION:
S4, NZS2
ADG CLASSIFICATION:
None allocated. Not a Dangerous Good.
UN NUMBER:
None allocated
E
E
E
M
M
M
E
E
E
R
R
R
G
G
G
E
E
E
N
N
N
C
C
C
Y
Y
Y
O
O
O
V
V
V
E
E
E
R
R
R
V
V
V
I
I
I
E
E
E
W
W
W
PHYSICAL DESCRIPTION & COLOUR
: Clear liquid. Presented in disposable glass syringe containing 1 mL
ODOUR:
No data.
MAJOR HEALTH HAZARDS:
possible risk of impaired fertility, possible risk of harm to the
unborn child.
P
P
P
O
O
O
T
T
T
E
E
E
N
N
N
T
T
T
I
I
I
A
A
A
L
L
L
H
H
H
E
E
E
A
A
A
L
L
L
T
T
T
H
H
H
E
E
E
F
F
F
F
F
F
E
E
E
C
C
C
T
T
T
S
S
S
This vaccine may be immunogenic in humans and may interfere with GnRF
function. This vaccine may cause atrophy
of sex organs, infertility and abortion by accidental self injection.
INHALATION
SHORT TERM EXPOSURE:
Significant inhalation exposure is considered to be unlikely.
Available data indicates that this
product is n